Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT-Reference-Cited by-同舟云学术

Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT

Published:2017-11-14 Issue:24 Volume:1 Page:2269-2279
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Ho Vincent T.¹²,Kim Haesook T.³,Bavli Natalie¹²,Mihm Martin⁴⁵,Pozdnyakova Olga⁶,Piesche Matthias¹²⁷,Daley Heather¹²,Reynolds Carol¹²,Souders Nicholas C.¹²,Cutler Corey¹²,Koreth John¹²,Alyea Edwin P.¹²,Antin Joseph H.¹²,Ritz Jerome¹²,Dranoff Glenn¹²,Soiffer Robert J.¹²

Affiliation:

1. Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA;

2. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;

3. Department of Biostatistics and Computation Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;

4. Department of Dermatology and

5. Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA;

6. Department of Hematopathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA; and

7. Biomedical Research Laboratories, Medicine Faculty, Catholic University of Maule, Talca, Chile

Abstract

Key Points GM-K562 admixed leukemia cell vaccination after allogeneic HSCT has biologic activity in MDS/AML. Postvaccination antibody response to angiopoeitin-2 is associated with improved outcomes.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/24/2269/879018/advances009084.pdf

Reference31 articles.

1. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens;Greiner;Haematologica,2006

2. Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias;Barrett;Clin Exp Immunol,2007

3. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia;Molldrem;Nat Med,2000

4. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia;Rezvani;Blood,2007

5. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation;Rousseau;Blood,2006

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Multifunctional Nanovaccines for Potent Personalized Immunotherapy of Acute Myeloid Leukemia;Advanced Materials;2024-08-22

2. A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treatment of follicular lymphoma;Leukemia & Lymphoma;2024-07-21

3. Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological malignancies;Cytotherapy;2022-10

4. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy;Leukemia;2021-11-29

5. Therapeutic cancer vaccine therapy for acute myeloid leukemia;Immunotherapy;2021-07